University of Helsinki
Klefström lab
Oncogenic signaling pathways as therapeutic targets in breast cancer
Our laboratory studies oncogene and tumor suppressor induced cancer-specific cellular programs, which cause therapeutic vulnerabilities in breast cancer.
News
Lab Retreat 2017
The annual Klefström research group lab retreat took place in November 2017. The two-day lab retreat inspired scientific discussions and debates across a wide range of cancer-related topics. After the scientific presentations of the day, KlefaLab members unwinded with a friendly game of bubble soccer. Additional time was taken to acknowledge the strengths of each lab member with a light-hearted “award” ceremony.
Klefström lab on facebook
Klefström Lab retreat in Tvärminne biological research station. Beware breast cancer, your days are numbered #cancer.
VeM-PD1 yhdistelmähoidosta viikonlopun Ilta- Sanomissa.
www.helsinki.fi/en/news/health-news/combination-treatment-including-diabetes-drug-and-immunothera...
helsinki.fi
Researchers in Finland have discovered a drug combination that collaborates with the cancer cells' own MYC oncoprotein, which in large quantities causes self-destruction of the cancer cells.When this combination is enhanced with immune system-boosting anti-PD-1 therapy, a more effective and long-las...Congratulations for my dream team. This research project took only about 10 years, from the first ideas and findings to completion of the study, but it is all well worth it. I believe so. Thanks guys, well done. rdcu.be/bkY9Y
idp.nature.com
Very positive news for clinical cancer research in Finland. A collaboration between Helsinki University Hospital and Pfizer (text in Finnish).